Elevated plasma interleukin-18 is a marker of insulin-resistance in type 2 diabetic and non-diabetic humans

被引:127
作者
Fischer, CP
Perstrup, LP
Berntsen, A
Eskildsen, P
Pedersen, BK
机构
[1] Univ Copenhagen, Ctr Inflammat & Metab, Dept Infect Dis, DK-2100 Copenhagen, Denmark
[2] Univ Copenhagen, Rigshosp, Copenhagen Muscle Res Ctr, DK-2100 Copenhagen, Denmark
[3] Univ Copenhagen, Fac Hlth Sci, DK-2100 Copenhagen, Denmark
[4] Roskilde Cty Psychiat Hosp Fjorden, Dept Med 3, Koge, Denmark
关键词
cytokines; epidemiology; inflammation; insulin resistance; type; 2; diabetes; obesity;
D O I
10.1016/j.clim.2005.07.008
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Elevated plasma IL-18 is present in several conditions sharing insulin-resistance as common trait, but the association with insulin-resistance per se is not established. Plasma/serum IL-6, IL-18, TNF-alpha, soluble TNF receptor 11 (sTNFR2), and C-reactive protein (CRP) were measured in 97 patients with type 2 diabetes (DM) and 84 non-diabetic controls (CON). The association with insulin-resistance-estimated using the homeostasis model assessment (HOMA-IR)-was analyzed using multivariate linear and logistic regression. Compared to CON, DM demonstrated higher plasma levels of IL-18 (P=0.001), IL-6 (P < 0.001), sTNFR2 (P=0.005), and CRP (P < 0.001), while TNF-a was lower (P=0.017). Plasma IL-18 increased across HOMA-IR quartiles in both DM and CON, both with and without adjustment for confounders (all P < 0.05). In contrast, neither IL-6, TNF-alpha, sTNFR2, nor CRP was associated with HOMA-IR in CON when adjusting for confounders. Accordingly, 50% increase of IL-18 corresponded to a marked increase of HOMA-IR in both DM and CON (DM: 26%, P=0.014; CON: 25%, P=0.003) after adjustment for confounders. Our results show that plasma IL-18 was associated with HOMA-IR independent of obesity and type 2 diabetes. (c) 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码:152 / 160
页数:9
相关论文
共 48 条
  • [1] Alberti KGMM, 1998, DIABETIC MED, V15, P539, DOI 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO
  • [2] 2-S
  • [3] Relationships of plasma interleukin-18 concentrations to hyperhomocysteinemia and carotid intimal-media wall thickness in patients with type 2 diabetes
    Aso, Y
    Okumura, K
    Takebayashi, K
    Wakabayashi, S
    Inukai, T
    [J]. DIABETES CARE, 2003, 26 (09) : 2622 - 2627
  • [4] Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina
    Blankenberg, S
    Tiret, L
    Bickel, C
    Peetz, D
    Cambien, F
    Meyer, J
    Rupprecht, HJ
    [J]. CIRCULATION, 2002, 106 (01) : 24 - 30
  • [5] Interleukin-6 and tumor necrosis factor-α are not increased in patients with Type 2 diabetes:: evidence that plasma interleukin-6 is related to fat mass and not insulin responsiveness
    Carey, AL
    Bruce, CR
    Sacchetti, M
    Anderson, MJ
    Olsen, DB
    Saltin, B
    Hawley, JA
    Febbraio, MA
    [J]. DIABETOLOGIA, 2004, 47 (06) : 1029 - 1037
  • [6] Overview of interleukin-18:: more than an interferon-γ inducing factor
    Dinarello, CA
    Novick, D
    Puren, AJ
    Fantuzzi, G
    Shapiro, L
    Mühl, H
    Yoon, DY
    Reznikov, LL
    Kim, SH
    Rubinstein, M
    [J]. JOURNAL OF LEUKOCYTE BIOLOGY, 1998, 63 (06) : 658 - 664
  • [7] IL-18:: A TH1-inducing, proinflammatory cytokine and new member of the IL-1 family
    Dinarello, CA
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1999, 103 (01) : 11 - 24
  • [8] Dinarello CA, 2001, ANN RHEUM DIS, V60, pIII18
  • [9] SOCS-3 inhibits insulin signaling and is up-regulated in response to tumor necrosis factor-α in the adipose tissue of obese mice
    Emanuelli, B
    Peraldi, P
    Filloux, C
    Chavey, C
    Freidinger, K
    Hilton, DJ
    Hotamisligil, GS
    Van Obberghen, E
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (51) : 47944 - 47949
  • [10] Serum interleukin-18 concentrations are increased in the polycystic ovary syndrome:: Relationship to insulin resistance and to obesity
    Escobar-Morreale, HF
    Botella-Carretero, JI
    Villuendas, G
    Sancho, J
    San Millán, JL
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (02) : 806 - 811